Bio-Rad Laboratories, Inc. (NYSE: BIO) is a Healthcare company (Medical - Devices) with a market capitalization of $9.6B. The Maz Rating grades it against the other companies in its sector.
Bio-Rad Laboratories, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $358.19, Bio-Rad Laboratories, Inc. trades at 9.4x trailing earnings, 3.7x sales and 1.3x book value, with an EV/EBITDA of 7.1. Over the last twelve months it generated about $2.6B of revenue and $1.0B of net income. It runs a gross margin of 51.3%, an operating margin of 4.6% and a net margin of 39.5%. It shows return on equity of 14.1%, return on invested capital of 0.9% and a free cash flow yield of 3.4%. On the balance sheet: a debt-to-equity ratio of 0.18 and a current ratio of 3.18. Over the past 52 weeks the share price ranged from $236.73 to $396.23, with a beta of 1.06.
Bio-Rad Laboratories, Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 1 Strong Buy, 7 Buy and 6 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Bio-Rad Laboratories, Inc. (BIO) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global, Dow Jones, MSCI and FTSE, and fails AAOIFI.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 12.0% / 30% · (Cash+Inv) / Mkt Cap (36m) 79.4% / 30% · Interest income / Revenue 1.52% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 12.0% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 16.6% / 33% · Receivables / Mkt Cap (36m) 4.23% / 49% · Interest income / Revenue 1.52% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 12.0% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 16.6% / 33.33% · Receivables / Mkt Cap (24m) 4.23% / 33.33% · Interest income / Revenue 1.52% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 12.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 15.4% / 33.33% · Receivables / Avg Assets (4Q) 4.26% / 33.33% · Interest income / Revenue 1.52% / 5% | Pass |
| FTSE | Debt / Total Assets 11.2% / 33.33% · (Cash+ST Inv) / Total Assets 15.4% / 33.33% · (Cash+Recv) / Total Assets 19.4% / 33.33% · Interest income / Revenue 1.52% / 5% | Pass |
It depends on the standard you follow. As of September 2026, Bio-Rad Laboratories, Inc. (BIO) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global, Dow Jones, MSCI and FTSE, and fails AAOIFI.
No. Bio-Rad Laboratories, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
About 1.52% of each dividend: Bio-Rad Laboratories, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.